Dr. Tuya Pal on Genetic Risk Assessment in Ovarian Cancer
Tuya Pal, MD, discusses the importance of genetic risk assessment shaping management guidelines in ovarian cancer.
Tuya Pal, MD, board-certified geneticist, Moffitt Cancer Center, discusses the importance of genetic risk assessment shaping management guidelines in ovarian cancer. Pal says tumor testing costs have drastically dropped over the past few years, and the tests have been much more widely undergone. The issue with these tests, she adds, is that the tests offer no way to know if mutations found in a tumor are specific solely to that tumor, or if these findings could be applied disease-wide.
Pal says genetic risk assessment has evolved from simply identifying risks to utilizing the information at point-of-care. She says a good example would be BRCA mutations in ovarian cancer, which can help guide surgical decisions for a patient.
Holloway Discusses the Rationale for PARP Inhibition in Advanced Ovarian Cancer
November 26th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Robert Holloway, MD, explored the state of PARP inhibitors for patients with advanced ovarian cancer including the PRIMA trial of niraparib.
Read More
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More
